Morphine

MS Contin, Kadian, Arymo, Duramorph, Infumorph, Mitigo

Opioid • Natural opioid agonist

Premium

NTICNS Depressant

Half-life

2-4 hours

Protein Binding

35%

Metabolized By

UGT2B7

External

Drugs.com

Boxed warning

Addiction/abuse/misuse
Respiratory depression
Neonatal withdrawal

Clinical alerts

Boxed warning

3 boxed warnings

Narrow therapeutic index

Small dose changes can cause toxicity or loss of effect

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Agonist at mu-opioid receptors

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Relapsing Multiple Sclerosis
·Alveolar Rhabdomyosarcoma
·Botryoid-Type Embryonal Rhabdomyosarcoma
·Embryonal Rhabdomyosarcoma
·Rhabdomyosarcoma

Interactions

2 curated · 2 major or contraindicated · select a row for management

Interacting drug	Severity	Effect
diazepam	contraindicated	Life-threatening respiratory depression.
lorazepam	major	Respiratory depression, profound sedation, potential overdose

Common adverse effects

Constipation
Nausea
Sedation
Respiratory depression
Pruritus

Food, alcohol & herbal

Alcohol · major

LIFE-THREATENING respiratory depression. CONTRAINDICATED.

Herbal

Kava (major) — Additive CNS and respiratory depression

Pharmacokinetics

Published parameters · PMID:9721623

Half-life: 2-4 hours
Protein binding: 35%
Metabolised by: UGT2B7
Clearance: 60 L/h; adult patients
Volume of distribution: 200 L
Bioavailability: 30%
Renally eliminated: 10%
Model: 2-compartment

Pregnancy & lactation

Not recorded for Morphine. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, curated interaction pairs, published PK literature.

Not a substitute for clinical judgement

Morphine

MS Contin, Kadian, Arymo, Duramorph, Infumorph, Mitigo

Opioid • Natural opioid agonist

Premium

NTICNS Depressant

Half-life

2-4 hours

Protein Binding

35%

Metabolized By

UGT2B7

External

Drugs.com

Boxed warning

Addiction/abuse/misuse
Respiratory depression
Neonatal withdrawal

Clinical alerts

Boxed warning

3 boxed warnings

Narrow therapeutic index

Small dose changes can cause toxicity or loss of effect

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Agonist at mu-opioid receptors

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Relapsing Multiple Sclerosis
·Alveolar Rhabdomyosarcoma
·Botryoid-Type Embryonal Rhabdomyosarcoma
·Embryonal Rhabdomyosarcoma
·Rhabdomyosarcoma

Interactions

2 curated · 2 major or contraindicated · select a row for management

Interacting drug	Severity	Effect
diazepam	contraindicated	Life-threatening respiratory depression.
lorazepam	major	Respiratory depression, profound sedation, potential overdose

Common adverse effects

Constipation
Nausea
Sedation
Respiratory depression
Pruritus

Food, alcohol & herbal

Alcohol · major

LIFE-THREATENING respiratory depression. CONTRAINDICATED.

Herbal

Kava (major) — Additive CNS and respiratory depression

Pharmacokinetics

Published parameters · PMID:9721623

Half-life: 2-4 hours
Protein binding: 35%
Metabolised by: UGT2B7
Clearance: 60 L/h; adult patients
Volume of distribution: 200 L
Bioavailability: 30%
Renally eliminated: 10%
Model: 2-compartment

Pregnancy & lactation

Not recorded for Morphine. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, curated interaction pairs, published PK literature.

Not a substitute for clinical judgement

Morphine Drug Profile | PharmaGraphX